Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2281-2288

  Prijić, Sanja ^a   Ugrina, Ivo ^b   Labar, Boris ^c   Nemet, Damir ^a,d   Batinić, Josip ^a,d   Zadro, Renata ^a   Ries, Sunčica ^a   Gjadrov Kuvedžić, Koraljka ^a   Davidović, Sanja ^a   Batinić, Drago ^a,d  

^a KBC Zagreb   (Croatia)

^b GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^c Centre for Expert Medicine   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Acute myeloid leukemia; P glycoprotein; PI3K Akt and MAPK signaling pathways

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SYNAPTOPHYSIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; AGE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; ENZYME PHOSPHORYLATION; EXTRACELLULAR SPACE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REGULATORY MECHANISM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MORTALITY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; P-GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84943397534     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.990012     Document Type: Article

References (64)

1. Rowe JM. Clinical progress in acute myeloid leukemia. Best Pract Res Clin Haematol 2008; 21: 597-599.
2. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
3. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976-982.
4. Mrozek K, Dohner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 2007; 14: 106-114.
5. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Eng J Med 2008; 358: 1909-1918.
6. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
7. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. Blood 2002; 100: 4372-4380.
8. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233-7239.
9. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous w association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
10. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
11. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911.
12. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463-3468.
13. Schnittiger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791-1799.
14. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747-3754.
15. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:interaction with other gene mutations. Blood 2005; 106: 3740-3746.
16. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype respresents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28: 570-577.
17. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favourable outcome. Blood 2009; 113: 3088-3091.
18. Pabst T, Eyholzer M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100: 1343-1346.
19. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal tandem duplication. Blood 2009; 113: 5090-5093.
20. Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukemia. Leukemia 2009; 23: 1029-1038.
21. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia:its significance as a prognostic variable. Leukemia 2003; 17: 995-997.
22. Tamburini J, Elie C, Bardet V, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007; 110: 1025-1028.
23. Sholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008; 35: 336-345.
24. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707.
25. Towatari M, Iida H, Tanimoto M, et al. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997; 11: 479-484.
26. McCubrey JA, Steelman LS, Kempf CR, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011; 226: 2762-2781.
27. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
28. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722.
29. Hamda H, Tsuruo T. Putification of the 170-to 180-kilodalton membrane glycoprotein associated with multidrug resistance-170-to 180-kilodalton membrane protein is an ATPase. J Biol Chem 1998; 263: 1454-1458.
30. Cordon-Cardo C, OBrien JP, Casalas D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-698.
31. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
32. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug-resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2739.
33. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
34. Arceci RJ, Croop JM, Horowitz SB, et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350-4354.
35. Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 1988; 48: 4926-4932.
36. Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-3008.
37. Horowitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15: 55-61.
38. Borg AG, Burgess R, Green LM, et al. Overexpression of lung-resistance protein and increased P-gp function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083-1091.
39. Nussler V, Pelka-Fleischer R, Zwierzina H, et al. P-glycoprotein expression in patient with acute leukemia-clinical relevance. Leukemia 1996; 10 (Suppl. 3): S23-S31.
40. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
41. Tazzari PL, Capellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427-438.
42. Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014; 32: 219-228.
43. Adès L, Chevret S, Raffoux E, et al.; European APL group. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 2013; 88: 556-559.
44. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in w acute myeloid leukemia. Blood 1987; 69: 744-749.
45. Huet S, Marie JP, Gualde N, et al. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by laboratories of the French Drug Resistance Network. Cytometry 1998; 34: 248-256.
46. Petriz J, Garcia-Lopez J. Flow cytometric analysis of P-glycoprotein function using Rhodamine 123. Leukemia 1997; 11: 1124-1130.
47. Available from: www.bdbiosciences.com/documents/Phosflow-Protocol-for-Human-PBMCs.pdf
48. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003; 55: 61-70.
49. Krutzik PO, Irish JM, Nolan GP, et al. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004; 110: 206-221.
50. Bardet V, Tamburini J, Ifrah N, et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006; 91: 757-764.
51. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 2: 971-972.
52. Gozzeti A, Le Beau MM. Fluorescence in situ hybridizations: uses and limitations. Semin Hematol 2000; 37: 320-333.
53. Schaffer LG, Slovak ML, Campbell LJ. ISCN 2009: an international system for human cytogenetic nomenclature: recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger Medical Scientific; 2009.
54. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
55. Hoeing JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat 2001; 55: 1-6.
56. Broxterman HJ, Sonneveld P, van Putten WJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000; 14: 1018-1024.
57. Park S, Park CH, Hahm ER, et al. Activation of Raf1 and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells. Cell Signal 2005; 17: 111-119.
58. Fang Y, Zhong L, Lin M, et al. MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS One 2013; 8: e66915.
59. Svensson S, Jirstrom K, Ryden L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005; 24: 4370-4379.
60. Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 2013; 27: 900-915.
61. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006; 5: 1799-1807.
62. Lin JC, Chang SY, Hsien DS, et al. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005; 174: 2022-2026.
63. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4: 342-359.
64. Bulavin DV, Fornace AJ Jr. P38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95-118.